In vivo experiments further confirmed that TSC1 knockdown significantly promoted tumor growth (with TSC1-deficient groups showing maximal tumor weight and volume), while anti-PD-1 monotherapy and rapamycin exhibited the most potent tumor-suppressive effects (Figure 6A). This evidence concerns the gene TSC1 and neoplasm.